Enhertu for HER2-Low Breast Cancer

At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer. Listen to the podcast to hear Dr. Wojciechowski explain: what HER2-low breast cancer is how Enhertu works how the results of the DESTINY-Breast-04 study will change practice